Lemtrada A Game Changer In MS, Genzyme Researchers Say
This article was originally published in The Pink Sheet Daily
Executive Summary
The paradigm shift long-lasting Lemtrada will excite, along with Aubagio’s gains since its launch in October, put Sanofi well on the road to its goal of multiple sclerosis leadership, Genzyme research execs say.
You may also be interested in...
Lemtrada Advisory Committee’s Flexibility May Not Make FDA Bend
Panel agrees with agency that Genzyme’s pivotal trials for MS drug don’t meet FDA approval standards, then casts conflicting votes supporting drug.
Lemtrada Advisory Committee’s Flexibility May Not Make FDA Bend
Panel agrees with agency that Genzyme’s pivotal trials for MS drug don’t meet FDA approval standards, then casts conflicting votes supporting drug.
Lemtrada Panel Review Pivots On What Constitutes An Adequate, Well-Controlled Trial
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will be asked whether open-label, rater-blinded trials meet approval standards for Sanofi/Genzyme’s Lemtrada sBLA; agency reviewers say no.